Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Biol Chem ; 397(5): 469-84, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-26760307

RESUMO

Macrophage elastase, or MMP-12, is mainly produced by alveolar macrophages and is believed to play a major role in the development of chronic obstructive pulmonary disease (COPD). The catalytic domain of MMP-12 is unique among MMPs in that it is very highly active on numerous substrates including elastin. However, measuring MMP-12 activity in biological fluids has been hampered by the lack of highly selective substrates. We therefore synthesized four series of fluorogenic peptide substrates based on the sequences of MMP-12 cleavage sites in its known substrates. Human MMP-12 efficiently cleaved peptide substrates containing a Pro at P3 in the sequence Pro-X-X↓Leu but lacked selectivity towards these substrates compared to other MMPs, including MMP-2, MMP-7, MMP-9 and MMP-13. On the contrary, the substrate Abz-RNALAVERTAS-EDDnp derived from the CXCR5 chemokine was the most selective substrate for MMP-12 ever reported. All substrates were cleaved more efficiently by full-length MMP-12 than by its catalytic domain alone, indicating that the C-terminal hemopexin domain influences substrate binding and/or catalysis. Docking experiments revealed unexpected interactions between the peptide substrate Abz-RNALAVERTAS-EDDn and MMP-12 residues. Most of our substrates were poorly cleaved by murine MMP-12 suggesting that human and murine MMP-12 have different substrate specificities despite their structural similarity.


Assuntos
Corantes Fluorescentes/química , Metaloproteinase 12 da Matriz/química , Oligopeptídeos/química , Animais , Biocatálise , Domínio Catalítico , Humanos , Camundongos , Simulação de Acoplamento Molecular , Especificidade da Espécie , Especificidade por Substrato
2.
Mol Ther ; 23(1): 24-31, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25189740

RESUMO

Elafin is a serine protease inhibitor produced by epithelial and immune cells with anti-inflammatory properties. Research has shown that dysregulated protease activity may elicit proteolytic cleavage of elafin, thereby impairing the innate immune function of the protein. The aim of this study was to generate variants of elafin (GG- and QQ-elafin) that exhibit increased protease resistance while retaining the biological properties of wild-type (WT) elafin. Similar to WT-elafin, GG- and QQ-elafin variants retained antiprotease activity and susceptibility to transglutaminase-mediated fibronectin cross-linking. However, in contrast to WT-elafin, GG- and QQ-elafin displayed significantly enhanced resistance to degradation when incubated with bronchoalveolar lavage fluid from patients with cystic fibrosis. Intriguingly, both variants, particularly GG-elafin, demonstrated improved lipopolysaccharide (LPS) neutralization properties in vitro. In addition, GG-elafin showed improved anti-inflammatory activity in a mouse model of LPS-induced acute lung inflammation. Inflammatory cell infiltration into the lung was reduced in lungs of mice treated with GG-elafin, predominantly neutrophilic infiltration. A reduction in MCP-1 levels in GG-elafin treated mice compared to the LPS alone treatment group was also demonstrated. GG-elafin showed increased functionality when compared to WT-elafin and may be of future therapeutic relevance in the treatment of lung diseases characterized by a protease burden.


Assuntos
Anti-Inflamatórios/farmacologia , Elafina/farmacologia , Pulmão/efeitos dos fármacos , Pneumonia/tratamento farmacológico , Inibidores de Proteases/farmacologia , Sequência de Aminoácidos , Animais , Anti-Inflamatórios/química , Líquido da Lavagem Broncoalveolar/química , Fibrose Cística/metabolismo , Fibrose Cística/patologia , Elafina/química , Elafina/genética , Fibronectinas/antagonistas & inibidores , Fibronectinas/metabolismo , Expressão Gênica , Humanos , Cinética , Lipopolissacarídeos , Pulmão/metabolismo , Pulmão/patologia , Masculino , Camundongos , Dados de Sequência Molecular , Pneumonia/induzido quimicamente , Pneumonia/metabolismo , Pneumonia/patologia , Inibidores de Proteases/química , Engenharia de Proteínas , Isoformas de Proteínas/química , Isoformas de Proteínas/genética , Isoformas de Proteínas/farmacologia , Proteólise/efeitos dos fármacos , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacologia , Transglutaminases/antagonistas & inibidores , Transglutaminases/metabolismo
3.
Chem Sci ; 14(4): 869-888, 2023 Jan 25.
Artigo em Inglês | MEDLINE | ID: mdl-36755705

RESUMO

Periodontopathogenic Tannerella forsythia uniquely secretes six peptidases of disparate catalytic classes and families that operate as virulence factors during infection of the gums, the KLIKK-peptidases. Their coding genes are immediately downstream of novel ORFs encoding the 98-132 residue potempins (Pot) A, B1, B2, C, D and E. These are outer-membrane-anchored lipoproteins that specifically and potently inhibit the respective downstream peptidase through stable complexes that protect the outer membrane of T. forsythia, as shown in vivo. Remarkably, PotA also contributes to bacterial fitness in vivo and specifically inhibits matrix metallopeptidase (MMP) 12, a major defence component of oral macrophages, thus featuring a novel and highly-specific physiological MMP inhibitor. Information from 11 structures and high-confidence homology models showed that the potempins are distinct ß-barrels with either a five-stranded OB-fold (PotA, PotC and PotD) or an eight-stranded up-and-down fold (PotE, PotB1 and PotB2), which are novel for peptidase inhibitors. Particular loops insert like wedges into the active-site cleft of the genetically-linked peptidases to specifically block them either via a new "bilobal" or the classic "standard" mechanism of inhibition. These results discover a unique, tightly-regulated proteolytic armamentarium for virulence and competence, the KLIKK-peptidase/potempin system.

4.
Biochem Soc Trans ; 39(5): 1441-6, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21936830

RESUMO

It is now clear that NSPs (neutrophil serine proteases), including elastase, Pr3 (proteinase 3) and CatG (cathepsin G) are major pathogenic determinants in chronic inflammatory disorders of the lungs. Two unglycosylated natural protease inhibitors, SLPI (secretory leucocyte protease inhibitor) and elafin, and its precursor trappin-2 that are found in the lungs, have therapeutic potential for reducing the protease-induced inflammatory response. This review examines the multifaceted roles of SLPI and elafin/trappin-2 in the context of their possible use as inhaled drugs for treating chronic lung diseases such as CF (cystic fibrosis) and COPD (chronic obstructive pulmonary disease).


Assuntos
Elafina/metabolismo , Inflamação/enzimologia , Pneumopatias/enzimologia , Inibidor Secretado de Peptidases Leucocitárias/metabolismo , Serina Proteases/metabolismo , Inibidores de Serina Proteinase/metabolismo , Aerossóis , Antibacterianos/metabolismo , Antibacterianos/uso terapêutico , Antifúngicos/metabolismo , Antifúngicos/uso terapêutico , Elafina/uso terapêutico , Humanos , Inflamação/tratamento farmacológico , Pneumopatias/tratamento farmacológico , Proteínas Secretadas Inibidoras de Proteinases/metabolismo , Proteínas Secretadas Inibidoras de Proteinases/uso terapêutico , Inibidor Secretado de Peptidases Leucocitárias/uso terapêutico , Inibidores de Serina Proteinase/uso terapêutico , Transglutaminases/metabolismo
5.
FEBS J ; 275(9): 2008-20, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18341586

RESUMO

Trappin-2 (also known as pre-elafin) is an endogenous inhibitor of neutrophil serine proteases and is involved in the control of excess proteolysis, especially in inflammatory events, along with the structurally related secretory leucocyte proteinase inhibitor. Secretory leucocyte proteinase inhibitor has been shown to have antibacterial and antifungal properties, whereas recent data indicate that trappin-2 has antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus. In the present study, we tested the antibacterial properties of trappin-2 towards other respiratory pathogens. We found that trappin-2, at concentrations of 5-20 microm, has significant activity against Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis and the pathogenic fungi Aspergillus fumigatus and Candida albicans, in addition to P. aeruginosa and S. aureus. A similar antimicrobial activity was observed with trappin-2 A62D/M63L, a trappin-2 variant that has lost its antiprotease properties, indicating that trappin-2 exerts its antibacterial effects through mechanisms independent from its intrinsic antiprotease capacity. Furthermore, the antibacterial and antifungal activities of trappin-2 were sensitive to NaCl and heparin, demonstrating that its mechanism of action is most probably dependent on its cationic nature. This enables trappin-2 to interact with the membranes of target organisms and disrupt them, as shown by our scanning electron microscopy analyses. Thus, trappin-2 not only provides an antiprotease shield, but also may play an important role in the innate defense of the human lungs and mucosae against pathogenic microorganisms.


Assuntos
Antibacterianos/metabolismo , Antifúngicos/metabolismo , Elafina/metabolismo , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/metabolismo , Dissulfetos/química , Relação Dose-Resposta a Droga , Elafina/farmacologia , Fibronectinas/metabolismo , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Negativas/ultraestrutura , Bactérias Gram-Positivas/efeitos dos fármacos , Bactérias Gram-Positivas/ultraestrutura , Heparina/farmacologia , Cinética , Modelos Químicos , Mutação , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , Proteínas Recombinantes/metabolismo , Inibidores de Serina Proteinase/genética , Inibidores de Serina Proteinase/isolamento & purificação , Cloreto de Sódio/farmacologia
6.
Biochimie ; 90(2): 284-95, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17964057

RESUMO

Elafin and SLPI are low-molecular weight proteins that were first identified as protease inhibitors in mucous fluids including lung secretions, where they help control excessive proteolysis due to neutrophil serine proteases (elastase, proteinase 3 and cathepsin G). Elafin and SLPI are structurally related in that both have a fold with a four-disulfide core or whey acidic protein (WAP) domain responsible for inhibiting proteases. Elafin is derived from a precursor, trappin-2 or pre-elafin, by proteolysis. Trappin-2, which is itself a protease inhibitor, has a unique N-terminal domain that enables it to become cross-linked to extracellular matrix proteins by transglutaminase(s). SLPI and elafin/trappin-2 are attractive candidates as therapeutic molecules for inhibiting neutrophil serine proteases in inflammatory lung diseases. Hence, they have become the WAP proteins most studied over the last decade. This review focuses on recent findings revealing that SLPI and elafin/trappin-2 have many biological functions as diverse as anti-bacterial, anti-fungal, anti-viral, anti-inflammatory and immuno-modulatory functions, in addition to their well-recognized role as protease inhibitors.


Assuntos
Elafina/fisiologia , Inibidor Secretado de Peptidases Leucocitárias/fisiologia , Sequência de Aminoácidos , Fármacos Anti-HIV/farmacologia , Anti-Infecciosos/farmacologia , Anti-Inflamatórios/farmacologia , Elafina/química , Elafina/farmacologia , Humanos , Pneumopatias/tratamento farmacológico , Dados de Sequência Molecular , Inibidor Secretado de Peptidases Leucocitárias/química , Inibidor Secretado de Peptidases Leucocitárias/farmacologia , Transglutaminases/metabolismo
7.
Biomol NMR Assign ; 10(1): 223-6, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26878852

RESUMO

Trappin-2 is a serine protease inhibitor with a very narrow inhibitory spectrum and has significant anti-microbial activities. It is a 10 kDa cationic protein composed of two distinct domains. The N-terminal domain (38 residues) named cementoin is known to be intrinsically disordered when it is not linked to the elafin. The C-terminal domain (57 residues), corresponding to elafin, is a cysteine-rich domain stabilized by four disulfide bridges and is characterized by a flat core and a flexible N-terminal part. To our knowledge, there is no structural data available on trappin-2. We report here the complete (1)H, (15)N and (13)C resonance assignment of the recombinant trappin-2 and the (1)H assignments of cementoin and elafin, under the same experimental conditions. This is the first step towards the 3D structure determination of the trappin-2.


Assuntos
Elafina/química , Ressonância Magnética Nuclear Biomolecular , Peptídeos/química , Sequência de Aminoácidos , Humanos , Domínios Proteicos
8.
FEBS J ; 272(22): 5883-93, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16279952

RESUMO

Neutrophil proteinase-mediated lung tissue destruction is prevented by inhibitors, including elafin and its precursor, trappin. We wanted to establish whether neutrophil-derived oxidants might impair the inhibitory function of these molecules. Myeloperoxidase/H(2)O(2) and N-chlorosuccinimide oxidation of the inhibitors was checked by mass spectrometry and enzymatic methods. Oxidation significantly lowers the affinities of the two inhibitors for neutrophil elastase (NE) and proteinase 3 (Pr3). This decrease in affinity is essentially caused by an increase in the rate of inhibitory complex dissociation. Oxidized elafin and trappin have, however, reasonable affinities for NE (K(i) = 4.0-9.2 x 10(-9) M) and for Pr3 (K(i) = 2.5-5.0 x 10(-8) M). These affinities are theoretically sufficient to allow the oxidized inhibitors to form tight binding complexes with NE and Pr3 in lung secretions where their physiological concentrations are in the micromolar range. Yet, they are unable to efficiently inhibit the elastolytic activity of the two enzymes. At their physiological concentration, fully oxidized elafin and trappin do not inhibit more than 30% of an equimolar concentration of NE or Pr3. We conclude that in vivo oxidation of elafin and trappin strongly impairs their activity. Inhibitor-based therapy of inflammatory lung diseases must be carried out using oxidation-resistant variants of these molecules.


Assuntos
Inibidores Enzimáticos/farmacologia , Precursores Enzimáticos/farmacologia , Elastase de Leucócito/antagonistas & inibidores , Proteínas/farmacologia , Serina Endopeptidases/metabolismo , Elafina , Inibidores Enzimáticos/química , Precursores Enzimáticos/química , Precursores Enzimáticos/genética , Variação Genética , Humanos , Cinética , Elastase de Leucócito/metabolismo , Espectrometria de Massas , Metionina/metabolismo , Mieloblastina , Oxirredução , Precursores de Proteínas/antagonistas & inibidores , Precursores de Proteínas/metabolismo , Proteínas Secretadas Inibidoras de Proteinases , Proteínas/química , Proteínas/genética , Proteínas Recombinantes/biossíntese
9.
Biochem Pharmacol ; 83(12): 1663-73, 2012 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-22465040

RESUMO

Neutrophil serine proteases (NSPs), including elastase, proteinase 3 and cathepsin G, play critical roles in the pathogenesis of chronic inflammatory lung diseases. The release of excess NSPs leads to the destruction of lung tissue and an overexuberant, sustained inflammatory response. Antiproteases could be valuable tools for controlling these NSP-mediated inflammatory events. We have examined the capacity of trappin-2 A62L, a potent engineered inhibitor of all three NSPs, to protect human lung A549 epithelial cells from the deleterious effects of NSPs. Trappin-2 A62L, significantly inhibited the detachment of A549 cells and the degradation of the tight-junction proteins, E-cadherin, ß-catenin and ZO-1, induced by each individual NSP and by activated neutrophils. Trappin-2 A62L also decreased the release of the pro-inflammatory cytokines IL-6 and IL-8 from A549 cells that had been stimulated with elastase or LPS. Trappin-2 A62D/M63L, a trappin-2 variant that has no antiprotease activity, has similar properties, suggesting that the anti-inflammatory action of trappin-2 is independent of its antiprotease activity. Interestingly, we present evidence that trappin-2 A62L, as well as wild-type trappin-2, enter A549 cells and move rapidly to the cytoplasm and nucleus, where they are likely to exert their anti-inflammatory effects. We have also demonstrated that trappin-2 A62L inhibits the early apoptosis of A549 cells mediated by NSPs. Thus, our data indicate that trappin-2 A62L is a powerful anti-protease and anti-inflammatory agent that could be used to develop a treatment for patients with inflammatory lung diseases.


Assuntos
Elafina/farmacologia , Pulmão/efeitos dos fármacos , Neutrófilos/efeitos dos fármacos , Proteínas Recombinantes de Fusão/farmacologia , Inibidor Secretado de Peptidases Leucocitárias/farmacologia , Inibidores de Serina Proteinase/farmacologia , Apoptose/efeitos dos fármacos , Linhagem Celular , Elafina/química , Células Epiteliais/efeitos dos fármacos , Imunofluorescência , Humanos , Pulmão/patologia , Neutrófilos/enzimologia , Proteólise , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes/química , Proteínas Recombinantes/farmacologia , Inibidor Secretado de Peptidases Leucocitárias/química
10.
PLoS One ; 6(6): e20976, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21687692

RESUMO

Human lungs contain secretory leukocyte protease inhibitor (SLPI), elafin and its biologically active precursor trappin-2 (pre-elafin). These important low-molecular weight inhibitors are involved in controlling the potentially deleterious proteolytic activities of neutrophil serine proteases including elastase, proteinase 3 and cathepsin G. We have shown previously that trappin-2, and to a lesser extent, elafin can be linked covalently to various extracellular matrix proteins by tissue transglutaminases and remain potent protease inhibitors. SLPI is composed of two distinct domains, each of which is about 40% identical to elafin, but it lacks consensus transglutaminase sequence(s), unlike trappin-2 and elafin. We investigated the actions of type 2 tissue transglutaminase and plasma transglutaminase activated factor XIII on SLPI. It was readily covalently bound to fibronectin or elastin by both transglutaminases but did not compete with trappin-2 cross-linking. Cross-linked SLPI still inhibited its target proteases, elastase and cathepsin G. We have also identified the transglutamination sites within SLPI, elafin and trappin-2 by mass spectrometry analysis of tryptic digests of inhibitors cross-linked to mono-dansyl cadaverin or to a fibronectin-derived glutamine-rich peptide. Most of the reactive lysine and glutamine residues in SLPI are located in its first N-terminal elafin-like domain, while in trappin-2, they are located in both the N-terminal cementoin domain and the elafin moiety. We have also demonstrated that the transglutamination substrate status of the cementoin domain of trappin-2 can be transferred from one protein to another, suggesting that it may provide transglutaminase-dependent attachment properties for engineered proteins. We have thus added to the corpus of knowledge on the biology of these potential therapeutic inhibitors of airway proteases.


Assuntos
Elafina/metabolismo , Proteínas de Ligação ao GTP/metabolismo , Inibidor Secretado de Peptidases Leucocitárias/metabolismo , Homologia de Sequência de Aminoácidos , Transglutaminases/metabolismo , Sequência de Aminoácidos , Animais , Cadaverina/análogos & derivados , Cadaverina/metabolismo , Bovinos , Elafina/química , Fator XIIIa/metabolismo , Fibronectinas/química , Fibronectinas/metabolismo , Glutamina , Cobaias , Humanos , Lisina , Espectrometria de Massas , Dados de Sequência Molecular , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/metabolismo , Ligação Proteica , Proteína 2 Glutamina gama-Glutamiltransferase , Inibidor Secretado de Peptidases Leucocitárias/química
11.
Biochimie ; 92(11): 1689-704, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20470858

RESUMO

Since its introduction by Georges Smith some 25 years ago, phage display has proved to be a powerful molecular technique for selecting proteins with desired biological properties from huge libraries. Early on, various protease inhibitor scaffolds were displayed at the surface of filamentous phages to select new inhibitors with shifted specificities and enhanced affinities towards one or more target protease(s). The past two decades have seen a number of natural protease inhibitors subjected to phage display, mostly to shift and increase their inhibitory specificity, but also to explore the molecular mechanisms by which they interact with their cognate enzymes with low or very high selectivity. This review focuses on the major uses of phage display in the field of protein protease inhibitors. The exquisite molecular mechanisms by which natural protease inhibitors prevent unwanted or excessive proteolysis in cells and tissues are also examined along with some of the general principles underlying the way phage display is applied to these molecules.


Assuntos
Peptídeo Hidrolases/metabolismo , Biblioteca de Peptídeos , Inibidores de Proteases/metabolismo , Engenharia de Proteínas/métodos , Animais , Humanos , Inovirus/genética , Peptídeo Hidrolases/química , Inibidores de Proteases/química , Proteínas/química , Proteínas/genética , Proteínas/metabolismo
12.
Protein Sci ; 18(3): 579-94, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19241385

RESUMO

The secretory leukocyte protease inhibitor (SLPI), elafin, and its biologically active precursor trappin-2 are endogeneous low-molecular weight inhibitors of the chelonianin family that control the enzymatic activity of neutrophil serine proteases (NSPs) like elastase, proteinase 3, and cathepsin G. These inhibitors may be of therapeutic value, since unregulated NSP activities are linked to inflammatory lung diseases. However SLPI inhibits elastase and cathepsin G but not proteinase 3, while elafin targets elastase and proteinase 3 but not cathepsin G. We have used two strategies to design polyvalent inhibitors of NSPs that target all three NSPs and may be used in the aerosol-based treatment of inflammatory lung diseases. First, we fused the elafin domain with the second inhibitory domain of SLPI to produce recombinant chimeras that had the inhibitory properties of both parent molecules. Second, we generated the trappin-2 variant, trappin-2 A62L, in which the P1 residue Ala is replaced by Leu, as in the corresponding position in SLPI domain 2. The chimera inhibitors and trappin-2 A62L are tight-binding inhibitors of all three NSPs with subnanomolar K(i)s, similar to those of the parent molecules for their respective target proteases. We have also shown that these molecules inhibit the neutrophil membrane-bound forms of all three NSPs. The trappin-2 A62L and elafin-SLPI chimeras, like wild-type elafin and trappin-2, can be covalently cross-linked to fibronectin or elastin by a tissue transglutaminase, while retaining their polypotent inhibition of NSPs. Therefore, the inhibitors described herein have the appropriate properties to be further evaluated as therapeutic anti-inflammatory agents.


Assuntos
Elafina/química , Neutrófilos/metabolismo , Proteínas Recombinantes de Fusão/química , Inibidor Secretado de Peptidases Leucocitárias/química , Serina Endopeptidases/metabolismo , Sequência de Aminoácidos , Catepsina G , Catepsinas/metabolismo , Relação Dose-Resposta a Droga , Descoberta de Drogas , Elafina/genética , Elafina/metabolismo , Humanos , Pneumopatias , Proteínas de Membrana/metabolismo , Modelos Moleculares , Dados de Sequência Molecular , Mieloblastina/metabolismo , Elastase Pancreática/metabolismo , Inibidores de Proteases/química , Inibidores de Proteases/metabolismo , Engenharia de Proteínas , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Inibidor Secretado de Peptidases Leucocitárias/genética , Inibidor Secretado de Peptidases Leucocitárias/metabolismo , Alinhamento de Sequência , Eletricidade Estática , Transglutaminases/metabolismo
13.
Biol Chem ; 386(4): 391-9, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15899702

RESUMO

A number of serine, cysteine, metallo- and acid proteases were evaluated for their ability to proteolytically cleave the serine protease inhibitor trappin-2, also known as pre-elafin, and to release elafin from its precursor. None of the metalloproteases or acid proteases examined cleaved trappin-2, while serine and cysteine proteases preferentially cleaved trappin-2 within its non-inhibitory N-terminal moiety. Cathepsin L, cathepsin K, plasmin, trypsin and tryptase were able to release elafin by cleaving the Lys 38 -Ala 39 peptide bond in trappin-2. However, purified tryptase appeared to be efficient at releasing elafin. Incubation of trappin-2 with purified mast cells first challenged with anti-immunoglobulin E or calcium ionophore A23187 resulted in the rapid generation of elafin. This proteolytic release of elafin from trappin-2 was inhibited in the presence of a tryptase inhibitor, suggesting that this mast cell enzyme was involved in the process. Finally, ex vivo incubation of trappin-2 with sputum from cystic fibrosis patients indicated the production of a proteolytic immunoreactive fragment with the same mass as that of native elafin. This cleavage did not occur when preincubating the sputum with polyclonal antibodies directed against tryptase. Taken together, these findings indicate that tryptase could likely be involved in the maturation of trappin-2 into elafin under physiological conditions.


Assuntos
Peptídeo Hidrolases/metabolismo , Proteínas/metabolismo , Serina Endopeptidases/química , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/metabolismo , Sequência de Aminoácidos , Animais , Bovinos , Células Cultivadas , Humanos , Hidrólise , Dados de Sequência Molecular , Pichia/genética , Proteínas Secretadas Inibidoras de Proteinases , Inibidores de Serina Proteinase/genética , Triptases
14.
Biochemistry ; 44(47): 15610-8, 2005 Nov 29.
Artigo em Inglês | MEDLINE | ID: mdl-16300411

RESUMO

Elafin and its precursor trappin-2 (also called pre-elafin) are potent protein inhibitors of neutrophil serine proteases such as leukocyte elastase and proteinase 3. Trappin-2 has unique conserved sequence motifs rich in Gln and Lys residues. These motifs are substrates for transglutaminases that may enable trappin-2 to be cross-linked to extracellular matrix proteins, thus anchoring the inhibitor at its site of action. We have used Western blotting and ELISA-based assays to demonstrate that both elafin and trappin-2 can be conjugated to various extracellular matrix proteins in vitro by a type 2 transglutaminase. Cross-linked elafin and trappin-2 still inhibited their target proteases. Surface plasmon resonance studies allowed the determination of the kinetic constants governing the interaction of fibronectin-bound elafin and trappin-2 with neutrophil elastase and proteinase 3. Both inhibitors were potent inhibitors when cross-linked to fibronectin by transglutamination, with equilibrium dissociation constants K(i) for their interaction with target proteases of 0.3 nM (elastase-elafin), 20 nM (proteinase 3-elafin), 0.3 nM (elastase-trappin-2), and 12 nM (proteinase 3-trappin-2). The conjugated inhibitors reacted more slowly with their target enzymes than did the soluble inhibitors, perhaps due to their immobilization, with association rate constants of 2-7 x 10(5) M(-)(1) s(-)(1) for elastase and 1-4 x 10(4) M(-)(1) s(-)(1) for proteinase 3. We believe this is the first demonstration that transglutaminase-mediated cross-linking of serine protease inhibitors to proteins preserves their inhibitory capacities.


Assuntos
Proteínas da Matriz Extracelular/metabolismo , Proteínas de Ligação ao GTP/metabolismo , Elastase de Leucócito/metabolismo , Precursores de Proteínas/metabolismo , Proteínas/metabolismo , Transglutaminases/metabolismo , Elafina , Fibronectinas/metabolismo , Humanos , Cinética , Elastase de Leucócito/antagonistas & inibidores , Mieloblastina , Proteína 2 Glutamina gama-Glutamiltransferase , Mapeamento de Interação de Proteínas , Proteínas Secretadas Inibidoras de Proteinases , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/metabolismo , Ressonância de Plasmônio de Superfície
15.
Eur J Biochem ; 271(12): 2370-8, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15182352

RESUMO

Elafin and its precursor, trappin-2 or pre-elafin, are specific endogenous inhibitors of human neutrophil elastase and proteinase 3 but not of cathepsin G. Both inhibitors belong, together with secretory leukocyte protease inhibitor, to the chelonianin family of canonical protease inhibitors of serine proteases. A cDNA coding either elafin or its precursor, trappin-2, was fused in frame with yeast alpha-factor cDNA and expressed in the Pichia pastoris yeast expression system. Full-length elafin or full-length trappin-2 were secreted into the culture medium with high yield, indicating correct processing of the fusion proteins by the yeast KEX2 signal peptidase. Both recombinant inhibitors were purified to homogeneity from concentrated culture medium by one-step cationic exchange chromatography and characterized by N-terminal amino acid sequencing, Western blot and kinetic studies. Both recombinant elafin and trappin-2 were found to be fast-acting inhibitors of pancreatic elastase, neutrophil elastase and proteinase 3 with k(ass) values of 2-4 x 10(6) m(-1).s(-1), while dissociation rate constants k(diss) were found to be in the 10(-4) s(-1) range, indicating low reversibility of the complexes. The equilibrium dissociation constant K(i) for the interaction of both recombinant inhibitors with their target enzymes was either directly measured for pancreatic elastase or calculated from k(ass) and k(diss) values for neutrophil elastase and proteinase 3. K(i) values were found to be in the 10(-10) molar range and virtually identical for both inhibitors. Based on the kinetic parameters determined here, it may be concluded that both recombinant elafin and trappin-2 may act as potent anti-inflammatory molecules and may be of therapeutic potential in the treatment of various inflammatory lung diseases.


Assuntos
Elastase de Leucócito/metabolismo , Pichia/metabolismo , Proteínas/metabolismo , Proteínas Recombinantes de Fusão/metabolismo , Serina Endopeptidases/metabolismo , Inibidores de Serina Proteinase/metabolismo , Animais , Humanos , Mieloblastina , Elastase Pancreática/genética , Elastase Pancreática/metabolismo , Pichia/genética , Precursores de Proteínas/genética , Precursores de Proteínas/metabolismo , Proteínas Secretadas Inibidoras de Proteinases , Proteínas/genética , Proteínas/isolamento & purificação , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/isolamento & purificação , Suínos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA